It is generally accepted that metabolism is able to shape the immune response. Only recently we are gaining awareness that the metabolic crosstalk between different tumor compartments strongly contributes to the harsh tumor microenvironment (TME) and ultimately impairs immune cell fitness and effector functions. The major aims of this review are to provide an overview on the immune system in cancer; to position oxygen shortage and metabolic competition as the ground of a restrictive TME and as important players in the anti-tumor immune response; to define how immunotherapies affect hypoxia/oxygen delivery and the metabolic landscape of the tumor; and vice versa, how oxygen and metabolites within the TME impinge on the success of immunotherapies. By analyzing preclinical and clinical endeavors, we will discuss how a metabolic characterization of the TME can identify novel targets and signatures that could be exploited in combination with standard immunotherapies and can help to predict the benefit of new and traditional immunotherapeutic drugs.

Immunity, hypoxia, and metabolism–the ménage à trois of cancer: Implications for immunotherapy

Mazzone M.
Last
2020-01-01

Abstract

It is generally accepted that metabolism is able to shape the immune response. Only recently we are gaining awareness that the metabolic crosstalk between different tumor compartments strongly contributes to the harsh tumor microenvironment (TME) and ultimately impairs immune cell fitness and effector functions. The major aims of this review are to provide an overview on the immune system in cancer; to position oxygen shortage and metabolic competition as the ground of a restrictive TME and as important players in the anti-tumor immune response; to define how immunotherapies affect hypoxia/oxygen delivery and the metabolic landscape of the tumor; and vice versa, how oxygen and metabolites within the TME impinge on the success of immunotherapies. By analyzing preclinical and clinical endeavors, we will discuss how a metabolic characterization of the TME can identify novel targets and signatures that could be exploited in combination with standard immunotherapies and can help to predict the benefit of new and traditional immunotherapeutic drugs.
2020
100
1
1
102
Cancer; Hypoxia; Immunometabolism; Immunotherapy; Metabolism; Animals; Humans; Neoplasms; Tumor Microenvironment; Hypoxia; Immunity; Immunotherapy
Riera-Domingo C.; Audige A.; Granja S.; Cheng W.-C.; Ho P.-C.; Baltazar F.; Stockmann C.; Mazzone M.
File in questo prodotto:
File Dimensione Formato  
Riera-Domingo et al, PhysiolRev, 2019.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 9.09 MB
Formato Adobe PDF
9.09 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
physrev.00018.2019.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 2.34 MB
Formato Adobe PDF
2.34 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1782153
Citazioni
  • ???jsp.display-item.citation.pmc??? 84
  • Scopus 180
  • ???jsp.display-item.citation.isi??? 173
social impact